Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

scientific article published on 21 March 2016

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JTHO.2016.03.008
P698PubMed publication ID27013408
P5875ResearchGate publication ID299344571

P50authorSuresh SenanQ37830477
P2093author name stringAdrianus J de Langen
Max Dahele
Ben Slotman
Wilko Verbakel
Sayed Hashemi
Hilâl Tekatli
Esther Nossent
Femke Spoelstra
Eva Bongers
Niels Haasbeek
Patricia De Haan
P433issue7
P921main subjectadaptive radiation therapyQ180507
P304page(s)1081-1089
P577publication date2016-03-21
P1433published inJournal of Thoracic OncologyQ2448056
P1476titleOutcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.
P478volume11

Reverse relations

cites work (P2860)
Q28079625A critical review of recent developments in radiotherapy for non-small cell lung cancer
Q38790915A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer
Q92846083Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors
Q99240991Chest wall toxicity after stereotactic radiation in early lung cancer: a systematic review
Q89869712Contrast enhanced oesophageal avoidance for stereotactic body radiotherapy: Barium vs. Gastrografin
Q99582784Dose-response relationship of stereotactic body radiotherapy for ultracentral tumor and comparison of efficacy with central tumor: a meta-analysis
Q61443804Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy
Q61804647Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation
Q42668963Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation
Q91734109Intratumoural renal cell carcinoma haemorrhage following stereotactic radiotherapy: a case report
Q92891968Moderately Hypofractionated Radiotherapy Alone for Stage I-IIB Non-small Cell Lung Cancer
Q92675935Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer
Q89924278Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors
Q48202266Phase I study of stereotactic body radiation therapy for centrally located stage IA non-small cell lung cancer (JROSG10-1).
Q94672120Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic
Q48282380Rethink radiotherapy - BIGART 2017.
Q92973685Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer
Q39135612SBRT for centrally localized NSCLC - What is too central?
Q53822924Standard of care in high-dose radiotherapy for localized non-small cell lung cancer.
Q64956876Stereotactic MR-Guided Online Adaptive Radiation Therapy (SMART) for Ultracentral Thorax Malignancies: Results of a Phase 1 Trial.
Q55224635Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Q89507738Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer
Q57172947Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances
Q55282076Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.
Q57177641Stereotactic body radiation therapy for lung, spine and oligometastatic disease: current evidence and future directions
Q61804651Stereotactic body radiotherapy for centrally located stage I non-small cell lung cancer
Q90017826Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes
Q90175125The evolving role of radiotherapy in non-small cell lung cancer
Q61804650The evolving toxicity profile of SBRT for lung cancer
Q55441971[Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer].

Search more.